KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Equity Average (2016 - 2025)

Historic Equity Average for Neogenomics (NEO) over the last 16 years, with Q4 2025 value amounting to $837.4 million.

  • Neogenomics' Equity Average fell 749.48% to $837.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $837.4 million, marking a year-over-year decrease of 749.48%. This contributed to the annual value of $869.5 million for FY2025, which is 569.32% down from last year.
  • Per Neogenomics' latest filing, its Equity Average stood at $837.4 million for Q4 2025, which was down 749.48% from $846.2 million recorded in Q3 2025.
  • In the past 5 years, Neogenomics' Equity Average ranged from a high of $1.1 billion in Q3 2021 and a low of $769.0 million during Q1 2021
  • Its 5-year average for Equity Average is $959.1 million, with a median of $948.1 million in 2023.
  • In the last 5 years, Neogenomics' Equity Average surged by 7307.41% in 2021 and then crashed by 1044.35% in 2022.
  • Quarter analysis of 5 years shows Neogenomics' Equity Average stood at $1.1 billion in 2021, then dropped by 10.44% to $1.0 billion in 2022, then decreased by 6.07% to $944.5 million in 2023, then fell by 4.15% to $905.3 million in 2024, then fell by 7.49% to $837.4 million in 2025.
  • Its Equity Average stands at $837.4 million for Q4 2025, versus $846.2 million for Q3 2025 and $871.2 million for Q2 2025.